The DOI matches its Crossref record; 142 of the 142 references it cites were found in a registry or an index.
Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?
Open accessAbstract
PURPOSE: Widespread antibiotic-resistant bacteria are threatening the arsenal of existing antibiotics. Not only are antibiotics less likely to be effective today, but their extensive use continues to drive the emergence of multidrug-resistant pathogens. A new-old antibacterial strategy with bacteriophages (phages) is under development, namely, phage therapy. Phages are targeted bacterial viruses with multiple antibacterial effector functions, which can reduce multidrug-resistant infections within the human body. This review summarizes recent phage therapy clinical trials and patient cases and outlines the fundamentals behind phage treatment strategies under development, mainly through bench-to-bedside approaches. We discuss the challenges that remain in phage therapy and the role of phages when combined with antibiotic therapy. METHODS: This narrative review presents the current knowledge and latest findings regarding phage therapy. Relevant case reports and research articles available through the Scopus and PubMed databases are discussed. FINDINGS: Although recent clinical data suggest the tolerability and, in some cases, efficacy of phage therapy, the clinical functionality still requires careful definition. The lack of well-controlled clinical trial data and complex regulatory frameworks have driven the most recent human data generation on a single-patient compassionate use basis. These cases often include the concomitant use of antibiotics, which makes it difficult to draw conclusions regarding the effectiveness of phages alone. However, human data support using antibiotics as phage potentiators and resistance breakers; thus, phage adjuvants are a promising avenue for near-term clinical development. Current knowledge gaps exist on the appropriate routes of administration, phage selection, frequency of administration, dosage, phage resistance, and pharmacokinetic and pharmacodynamic properties of the phages. In addition, we highlight that some phage therapies have mild adverse effects in patients. IMPLICATIONS: Although more translational research is needed before the clinical implementation is feasible, phage therapy may well be pivotal in safeguarding humans against antibiotic-resistant infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular mechanisms of antibiotic resistance
Blair, J. M. A., Webber, M. A., Baylay, A. J., Ogbolu, D. O., & Piddock, L. J. V. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3380 · Cited by 4,092
Mutations of bacteria from virus sensitivity to virus resistance
Luria, S. E., & Delbrück, M. (1943) · Genetics · doi:10.1093/genetics/28.6.491 · Cited by 3,894
Marine viruses — major players in the global ecosystem
Suttle, C. A. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1750 · Cited by 3,157
Bacteriophage resistance mechanisms
Labrie, S. J., Samson, J. E., & Moineau, S. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2315 · Cited by 2,397
Antibacterial drug discovery in the resistance era
Brown, E. D., & Wright, G. D. (2016) · Nature · doi:10.1038/nature17042 · Cited by 2,247
A brief history of the antibiotic era: lessons learned and challenges for the future
Aminov, R. I. (2010) · Frontiers in Microbiology · doi:10.3389/fmicb.2010.00134 · Cited by 1,628
Dedrick, R. M., Guerrero-Bustamante, C. A., Garlena, R. A., Russell, D. A., Ford, K., Harris, K., Gilmour, K. C., Soothill, J., Jacobs-Sera, D., Schooley, R. T., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0437-z · Cited by 1,410
Schooley, R. T., Biswas, B., Gill, J. J., Hernandez-Morales, A., Lancaster, J., Lessor, L., Barr, J. J., Reed, S. L., Rohwer, F., Benler, S., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00954-17 · Cited by 1,254
Pros and cons of phage therapy
Loc-Carrillo, C., & Abedon, S. T. (2011) · Bacteriophage · doi:10.4161/bact.1.2.14590 · Cited by 1,020
Phage diversity, genomics and phylogeny
Dion, M. B., Oechslin, F., & Moineau, S. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0311-5 · Cited by 960
The arms race between bacteria and their phage foes
Hampton, H. G., Watson, B. N. J., & Fineran, P. C. (2020) · Nature · doi:10.1038/s41586-019-1894-8 · Cited by 917
Lysogeny in nature: mechanisms, impact and ecology of temperate phages
Howard-Varona, C., Hargreaves, K. R., Abedon, S. T., & Sullivan, M. B. (2017) · The ISME Journal · doi:10.1038/ismej.2017.16 · Cited by 894
Jault, P., Leclerc, T., Jennes, S., Pirnay, J. P., Que, Y.-A., Resch, G., Rousseau, A. F., Ravat, F., Carsin, H., Le Floch, R., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30482-1 · Cited by 874
Wright, A., Hawkins, C. H., Änggård, E. E., & Harper, D. R. (2009) · Clinical Otolaryngology · doi:10.1111/j.1749-4486.2009.01973.x · Cited by 864
Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa
Chan, B. K., Sistrom, M., Wertz, J. E., Kortright, K. E., Narayan, D., & Turner, P. E. (2016) · Scientific Reports · doi:10.1038/srep26717 · Cited by 715
Diverse Functions of Restriction-Modification Systems in Addition to Cellular Defense
Vasu, K., & Nagaraja, V. (2013) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00044-12 · Cited by 618
Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and Colitis
Gogokhia, L., Buhrke, K., Bell, R., Hoffman, B., Brown, D. G., Hanke-Gogokhia, C., Ajami, N. J., Wong, M. C., Ghazaryan, A., Valentine, J. F., et al. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.01.008 · Cited by 609
Antibiotic Adjuvants: Rescuing Antibiotics from Resistance
Wright, G. D. (2016) · Trends in Microbiology · doi:10.1016/j.tim.2016.06.009 · Cited by 604
Resistance Development to Bacteriophages Occurring during Bacteriophage Therapy
Oechslin, F. (2018) · Viruses · doi:10.3390/v10070351 · Cited by 594
Human Volunteers Receiving Escherichia coli Phage T4 Orally: a Safety Test of Phage Therapy
Bruttin, A., & Brüssow, H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.7.2874-2878.2005 · Cited by 563
Phage-Antibiotic Synergy (PAS): β-Lactam and Quinolone Antibiotics Stimulate Virulent Phage Growth
Comeau, A., Tétart, F., Trojet, S. N., Prère, M. F., & Krisch, H. M. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000799 · Cited by 554
Manrique, P., Bolduc, B., Walk, S. T., van der Oost, J., de Vos, W. M., & Young, M. J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1601060113 · Cited by 545
Bacteriophages and their genomes
Hatfull, G. F., & Hendrix, R. W. (2011) · Current Opinion in Virology · doi:10.1016/j.coviro.2011.06.009 · Cited by 541
Sarker, S. A., Sultana, S., Reuteler, G., Moine, D., Descombes, P., Charton, F., Bourdin, G., McCallin, S., Ngom-Bru, C., Neville, T., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2015.12.023 · Cited by 533
Smith, H. W., & Huggins, M. B. (1982) · Microbiology · doi:10.1099/00221287-128-2-307 · Cited by 518
Bacteriophage-encoded depolymerases: their diversity and biotechnological applications
Pires, D. P., Oliveira, H., Melo, L. D. R., Sillankorva, S., & Azeredo, J. (2016) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-015-7247-0 · Cited by 517
Population and evolutionary dynamics of phage therapy
Levin, B. R., & Bull, J. J. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro822 · Cited by 511
Phage treatment of an aortic graft infected with Pseudomonas aeruginosa
Chan, B. K., Turner, P. E., Kim, S., Mojibian, H. R., Elefteriades, J. A., & Narayan, D. (2018) · Evolution, Medicine, and Public Health · doi:10.1093/emph/eoy005 · Cited by 501
Roach, D. R., Leung, C. Y., Henry, M., Morello, E., Singh, D., Di Santo, J. P., Weitz, J. S., & Debarbieux, L. (2017) · Cell Host & Microbe · doi:10.1016/j.chom.2017.06.018 · Cited by 484
Self-citationComputational approaches to predict bacteriophage–host relationships
Edwards, R. A., McNair, K., Faust, K., Raes, J., & Dutilh, B. E. (2016) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuv048 · Cited by 475
Safety of bacteriophage therapy in severe Staphylococcus aureus infection
Petrovic Fabijan, A., Lin, R. C. Y., Ho, J., Maddocks, S., Ben Zakour, N. L., Iredell, J. R., Westmead Bacteriophage Therapy Team, Khalid, A., Venturini, C., Chard, R., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-019-0634-z · Cited by 471
Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial
Rhoads, D. D., Wolcott, R. D., Kuskowski, M. A., Wolcott, B. M., Ward, L. S., & Sulakvelidze, A. (2009) · Journal of Wound Care · doi:10.12968/jowc.2009.18.6.42801 · Cited by 468
Lenski, R. E., & Levin, B. R. (1985) · The American Naturalist · doi:10.1086/284364 · Cited by 460
Imamovic, L., & Sommer, M. O. A. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006609 · Cited by 444
Dosing Frequency and Medication Adherence in Chronic Disease
Coleman, C. I., Limone, B., Sobieraj, D. M., Lee, S., Roberts, M. S., Kaur, R., & Alam, T. (2012) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2012.18.7.527 · Cited by 432
Anti-CRISPR: discovery, mechanism and function
Pawluk, A., Davidson, A. R., & Maxwell, K. L. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.120 · Cited by 401
Bacteriophage Transcytosis Provides a Mechanism To Cross Epithelial Cell Layers
Nguyen, S., Baker, K., Padman, B. S., Patwa, R., Dunstan, R. A., Weston, T. A., Schlosser, K., Bailey, B., Lithgow, T., Lazarou, M., et al. (2017) · mBio · doi:10.1128/mbio.01874-17 · Cited by 378
Clinical Aspects of Phage Therapy
Międzybrodzki, R., Borysowski, J., Weber-Dąbrowska, B., Fortuna, W., Letkiewicz, S., Szufnarowski, K., Pawełczyk, Z., Rogóż, P., Kłak, M., Wojtasik, E., et al. (2012) · Advances in Virus Research · doi:10.1016/b978-0-12-394438-2.00003-7 · Cited by 373
More Is Better: Selecting for Broad Host Range Bacteriophages
Ross, A., Ward, S., & Hyman, P. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01352 · Cited by 367
Phage on tap–a quick and efficient protocol for the preparation of bacteriophage laboratory stocks
Bonilla, N., Rojas, M. I., Netto Flores Cruz, G., Hung, S.-H., Rohwer, F., & Barr, J. J. (2016) · PeerJ · doi:10.7717/peerj.2261 · Cited by 353
Pirnay, J.-P., Verbeken, G., Ceyssens, P.-J., Huys, I., De Vos, D., Ameloot, C., & Fauconnier, A. (2018) · Viruses · doi:10.3390/v10020064 · Cited by 347
Fighting Pathogenic Bacteria on Two Fronts: Phages and Antibiotics as Combined Strategy
Tagliaferri, T. L., Jansen, M., & Horz, H.-P. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00022 · Cited by 345
Harper, D., Parracho, H., Walker, J., Sharp, R., Hughes, G., Werthén, M., Lehman, S., & Morales, S. (2014) · Antibiotics · doi:10.3390/antibiotics3030270 · Cited by 342
PHANOTATE: a novel approach to gene identification in phage genomes
McNair, K., Zhou, C., Dinsdale, E. A., Souza, B., & Edwards, R. A. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz265 · Cited by 328
Oechslin, F., Piccardi, P., Mancini, S., Gabard, J., Moreillon, P., Entenza, J. M., Resch, G., & Que, Y.-A. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiw632 · Cited by 325
Phage Therapy: Going Temperate?
Monteiro, R., Pires, D. P., Costa, A. R., & Azeredo, J. (2019) · Trends in Microbiology · doi:10.1016/j.tim.2018.10.008 · Cited by 303
The Phage Therapy Paradigm: Prêt-à-Porter or Sur-mesure?
Pirnay, J.-P., De Vos, D., Verbeken, G., Merabishvili, M., Chanishvili, N., Vaneechoutte, M., Zizi, M., Laire, G., Lavigne, R., Huys, I., et al. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0313-5 · Cited by 298
Are There 10 31 Virus Particles on Earth, or More, or Fewer?
Mushegian, A. R. (2020) · Journal of Bacteriology · doi:10.1128/jb.00052-20 · Cited by 291
Early clinical experience of bacteriophage therapy in 3 lung transplant recipients
Aslam, S., Courtwright, A. M., Koval, C., Lehman, S. M., Morales, S., Furr, C.-L. L., Rosas, F., Brownstein, M. J., Fackler, J. R., Sisson, B. M., et al. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15503 · Cited by 285
The strange history of phage therapy
Summers, W. C. (2012) · Bacteriophage · doi:10.4161/bact.20757 · Cited by 284
Abedon, S., & Thomas-Abedon, C. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725410 · Cited by 284
Wiggins, B. A., & Alexander, M. (1985) · Applied and Environmental Microbiology · doi:10.1128/aem.49.1.19-23.1985 · Cited by 275
Standardized bacteriophage purification for personalized phage therapy
Luong, T., Salabarria, A.-C., Edwards, R. A., & Roach, D. R. (2020) · Nature Protocols · doi:10.1038/s41596-020-0346-0 · Cited by 274
Self-citationPHACTS, a computational approach to classifying the lifestyle of phages
McNair, K., Bailey, B. A., & Edwards, R. A. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts014 · Cited by 269
Forti, F., Roach, D. R., Cafora, M., Pasini, M. E., Horner, D. S., Fiscarelli, E. V., Rossitto, M., Cariani, L., Briani, F., Debarbieux, L., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02573-17 · Cited by 269
Self-citationMcCallin, S., Alam Sarker, S., Barretto, C., Sultana, S., Berger, B., Huq, S., Krause, L., Bibiloni, R., Schmitt, B., Reuteler, G., et al. (2013) · Virology · doi:10.1016/j.virol.2013.05.022 · Cited by 265
Nir-Paz, R., Gelman, D., Khouri, A., Sisson, B. M., Fackler, J., Alkalay-Oren, S., Khalifa, L., Rimon, A., Yerushalmy, O., Bader, R., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz222 · Cited by 265
Prokaryote viruses studied by electron microscopy
Ackermann, H.-W., & Prangishvili, D. (2012) · Archives of Virology · doi:10.1007/s00705-012-1383-y · Cited by 262
Law, N., Logan, C., Yung, G., Furr, C.-L. L., Lehman, S. M., Morales, S., Rosas, F., Gaidamaka, A., Bilinsky, I., Grint, P., et al. (2019) · Infection · doi:10.1007/s15010-019-01319-0 · Cited by 260
Jennes, S., Merabishvili, M., Soentjens, P., Pang, K. W., Rose, T., Keersebilck, E., Soete, O., François, P.-M., Teodorescu, S., Verween, G., et al. (2017) · Critical Care · doi:10.1186/s13054-017-1709-y · Cited by 248
Antimicrobial bacteriophage-derived proteins and therapeutic applications
Roach, D. R., & Donovan, D. M. (2015) · Bacteriophage · doi:10.1080/21597081.2015.1062590 · Cited by 245
Self-citationSynergistic phage-antibiotic combinations for the control of Escherichia coli biofilms in vitro
Ryan, E. M., Alkawareek, M. Y., Donnelly, R. F., & Gilmore, B. F. (2012) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.2012.00977.x · Cited by 240
EFFECT OF RESOURCE ENRICHMENT ON A CHEMOSTAT COMMUNITY OF BACTERIA AND BACTERIOPHAGE
Bohannan, B. J. M., & Lenski, R. E. (1997) · Ecology · doi:10.1890/0012-9658(1997)078[2303:eoreoa]2.0.co;2 · Cited by 239
Phage Therapy for a Multidrug-Resistant Acinetobacter baumannii Craniectomy Site Infection
LaVergne, S., Hamilton, T., Biswas, B., Kumaraswamy, M., Schooley, R. T., & Wooten, D. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy064 · Cited by 239
Kamal, F., & Dennis, J. J. (2015) · Applied and Environmental Microbiology · doi:10.1128/aem.02850-14 · Cited by 224
Overcoming the Phage Replication Threshold: a Mathematical Model with Implications for Phage Therapy
Kasman, L. M., Kasman, A., Westwater, C., Dolan, J., Schmidt, M. G., & Norris, J. S. (2002) · Journal of Virology · doi:10.1128/jvi.76.11.5557-5564.2002 · Cited by 221
Phage Neutralization by Sera of Patients Receiving Phage Therapy
Łusiak-Szelachowska, M., Żaczek, M., Weber-Dąbrowska, B., Międzybrodzki, R., Kłak, M., Fortuna, W., Letkiewicz, S., Rogóż, P., Szufnarowski, K., Jończyk-Matysiak, E., et al. (2014) · Viral Immunology · doi:10.1089/vim.2013.0128 · Cited by 218
A bacteriophages journey through the human body
Barr, J. J. (2017) · Immunological Reviews · doi:10.1111/imr.12565 · Cited by 216
Experimental phage therapy of burn wound infection: difficult first steps.
Rose, T., Verbeken, G., Vos, D. D., Merabishvili, M., Vaneechoutte, M., Lavigne, R., Jennes, S., Zizi, M., & Pirnay, J. (2014) · PubMed · Cited by 213
Bacteriophages and their Enzymes in Biofilm Control
Chan, B., & Abedon, S. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140905112311 · Cited by 212
Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa
Waters, E. M., Neill, D. R., Kaman, B., Sahota, J. S., Clokie, M. R. J., Winstanley, C., & Kadioglu, A. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-209265 · Cited by 212
Dąbrowska, K., & Abedon, S. T. (2019) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00012-19 · Cited by 212
Febvre, H. P., Rao, S., Gindin, M., Goodwin, N. D. M., Finer, E., Vivanco, J. S., Lu, S., Manter, D. K., Wallace, T. C., & Weir, T. L. (2019) · Nutrients · doi:10.3390/nu11030666 · Cited by 188
Therapy of Experimental Pseudomonas Infections with a Nonreplicating Genetically Modified Phage
Hagens, S., Habel, A., von Ahsen, U., von Gabain, A., & Bläsi, U. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.10.3817-3822.2004 · Cited by 187
Oral Application of T4 Phage Induces Weak Antibody Production in the Gut and in the Blood
Majewska, J., Beta, W., Lecion, D., Hodyra-Stefaniak, K., Kłopot, A., Kaźmierczak, Z., Miernikiewicz, P., Piotrowicz, A., Ciekot, J., Owczarek, B., et al. (2015) · Viruses · doi:10.3390/v7082845 · Cited by 186
El Haddad, L., Harb, C. P., Gebara, M. A., Stibich, M. A., & Chemaly, R. F. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy947 · Cited by 185
Characterizing Phage Genomes for Therapeutic Applications
Philipson, C., Voegtly, L., Lueder, M., Long, K., Rice, G., Frey, K., Biswas, B., Cer, R., Hamilton, T., & Bishop-Lilly, K. (2018) · Viruses · doi:10.3390/v10040188 · Cited by 183
Ooi, M. L., Drilling, A. J., Morales, S., Fong, S., Moraitis, S., Macias-Valle, L., Vreugde, S., Psaltis, A. J., & Wormald, P.-J. (2019) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2019.1191 · Cited by 181
Bacteriophage interactions with mammalian tissue: Therapeutic applications
Huh, H., Wong, S., St. Jean, J., & Slavcev, R. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.01.003 · Cited by 179
Tkhilaishvili, T., Winkler, T., Müller, M., Perka, C., & Trampuž, A. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00924-19 · Cited by 179
CRISPR-Cas: an efficient tool for genome engineering of virulent bacteriophages
Martel, B., & Moineau, S. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku628 · Cited by 178
Antibiotic collateral sensitivity is contingent on the repeatability of evolution
Nichol, D., Rutter, J., Bryant, C., Hujer, A. M., Lek, S., Adams, M. D., Jeavons, P., Anderson, A. R. A., Bonomo, R. A., & Scott, J. G. (2019) · Nature Communications · doi:10.1038/s41467-018-08098-6 · Cited by 174
Akturk, E., Oliveira, H., Santos, S. B., Costa, S., Kuyumcu, S., Melo, L. D. R., & Azeredo, J. (2019) · Antibiotics · doi:10.3390/antibiotics8030103 · Cited by 172
Bacteriophage Therapy for Critical Infections Related to Cardiothoracic Surgery
Rubalskii, E., Ruemke, S., Salmoukas, C., Boyle, E. C., Warnecke, G., Tudorache, I., Shrestha, M. L., Schmitto, J. D., Martens, A., Rojas, S. V., et al. (2020) · Antibiotics · doi:10.3390/antibiotics9050232 · Cited by 172
Corbellino, M., Kieffer, N., Kutateladze, M., Balarjishvili, N., Leshkasheli, L., Askilashvili, L., Tsertsvadze, G., Rimoldi, S. G., Nizharadze, D., Hoyle, N., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz782 · Cited by 169
Effects of sunlight on bacteriophage viability and structure
Wommack, K. E., Hill, R. T., Muller, T. A., & Colwell, R. R. (1996) · Applied and Environmental Microbiology · doi:10.1128/aem.62.4.1336-1341.1996 · Cited by 168
Resistance Evolution against Phage Combinations Depends on the Timing and Order of Exposure
Wright, R. C. T., Friman, V., Smith, M. C. M., & Brockhurst, M. A. (2019) · mBio · doi:10.1128/mbio.01652-19 · Cited by 167
Synergy as a rationale for phage therapy using phage cocktails
Schmerer, M. W., Molineux, I. J., & Bull, J. J. (2014) · PeerJ · doi:10.7717/peerj.590 · Cited by 166
On-Demand Isolation of Bacteriophages Against Drug-Resistant Bacteria for Personalized Phage Therapy
Mattila, S., Ruotsalainen, P., & Jalasvuori, M. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.01271 · Cited by 165
Fong, S. A., Drilling, A., Morales, S., Cornet, M. E., Woodworth, B. A., Fokkens, W. J., Psaltis, A. J., Vreugde, S., & Wormald, P.-J. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00418 · Cited by 164
Adapted Bacteriophages for Treating Urinary Tract Infections
Ujmajuridze, A., Chanishvili, N., Goderdzishvili, M., Leitner, L., Mehnert, U., Chkhotua, A., Kessler, T. M., & Sybesma, W. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01832 · Cited by 163
Phage Therapy Regulation: From Night to Dawn
Fauconnier, A. (2019) · Viruses · doi:10.3390/v11040352 · Cited by 162
Jikia, D., Chkhaidze, N., Imedashvili, E., Mgaloblishvili, I., Tsitlanadze, G., Katsarava, R. D., Morris, J. G., & Sulakvelidze, A. (2005) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.2004.01600.x · Cited by 160
Segall, A. M., Roach, D. R., & Strathdee, S. A. (2019) · Current Opinion in Microbiology · doi:10.1016/j.mib.2019.03.005 · Cited by 160
Self-citationOnsea, J., Soentjens, P., Djebara, S., Merabishvili, M., Depypere, M., Spriet, I., De Munter, P., Debaveye, Y., Nijs, S., Vanderschot, P., et al. (2019) · Viruses · doi:10.3390/v11100891 · Cited by 160
Phage-antibiotic synergism: a possible approach to combatting Pseudomonas aeruginosa
Knezevic, P., Curcin, S., Aleksic, V., Petrusic, M., & Vlaski, L. (2013) · Research in Microbiology · doi:10.1016/j.resmic.2012.08.008 · Cited by 159
Clostridium difficile phages: still difficult?
Hargreaves, K. R., & Clokie, M. R. J. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00184 · Cited by 156
Expanding the Diversity of Mycobacteriophages: Insights into Genome Architecture and Evolution
Pope, W. H., Jacobs‐Sera, D., Russell, D. A., Peebles, C. L., Al-Atrache, Z., Alcoser, T. A., Alexander, L. M., Alfano, M. B., Alford, S. T., Amy, N. E., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016329 · Cited by 154
Big Impact of the Tiny: Bacteriophage–Bacteria Interactions in Biofilms
Hansen, M. F., Svenningsen, S. L., Røder, H. L., Middelboe, M., & Burmølle, M. (2019) · Trends in Microbiology · doi:10.1016/j.tim.2019.04.006 · Cited by 152
Costs of CRISPR-Cas-mediated resistance inStreptococcus thermophilus
Vale, P. F., Lafforgue, G., Gatchitch, F., Gardan, R., Moineau, S., & Gandon, S. (2015) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2015.1270 · Cited by 149
Coevolution can reverse predator–prey cycles
Cortez, M. H., & Weitz, J. S. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317693111 · Cited by 149
Refractory Pseudomonas Bacteremia in a 2-Year-Old Sterilized by Bacteriophage Therapy
Duplessis, C. A., Biswas, B., Hanisch, B. R., Perkins, M., Henry, M. S., Quinones, J., Wolfe, D., Estrella, L. A., & Hamilton, T. (2017) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/pix056 · Cited by 148
Hoyle, N. S., Zhvania, P., Balarjishvili, N., Bolkvadze, D., Nadareishvili, L., Nizharadze, D., Wittmann, J., Rohde, C., & Kutateladze, M. (2018) · Research in Microbiology · doi:10.1016/j.resmic.2018.05.001 · Cited by 145
Lehti, T. A., Pajunen, M. I., Skog, M. S., & Finne, J. (2017) · Nature Communications · doi:10.1038/s41467-017-02057-3 · Cited by 142
Phage Therapy in a 16-Year-Old Boy with Netherton Syndrome
Zhvania, P., Hoyle, N. S., Nadareishvili, L., Nizharadze, D., & Kutateladze, M. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00094 · Cited by 140
Żaczek, M., Łusiak-Szelachowska, M., Jończyk‐Matysiak, E., Weber‐Dąbrowska, B., Międzybrodzki, R., Owczarek, B., Kopciuch, A., Fortuna, W., Rogóż, P., & Górski, A. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01681 · Cited by 138
Pharmacological limitations of phage therapy
Nilsson, A. S. (2019) · Upsala Journal of Medical Sciences · doi:10.1080/03009734.2019.1688433 · Cited by 138
Coulter, L. B., McLean, R. J. C., Rohde, R. E., & Aron, G. M. (2014) · Viruses · doi:10.3390/v6103778 · Cited by 137
González-Menéndez, E., Fernández, L., Gutiérrez, D., Rodríguez, A., Martínez, B., & García, P. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205728 · Cited by 121
Bacteriophage Resistance Alters Antibiotic-Mediated Intestinal Expansion of Enterococci
Chatterjee, A., Johnson, C. N., Luong, P., Hullahalli, K., McBride, S. W., Schubert, A. M., Palmer, K. L., Carlson, P. E., & Duerkop, B. A. (2019) · Infection and Immunity · doi:10.1128/iai.00085-19 · Cited by 116
Phage control of dual species biofilms ofPseudomonas fluorescensandStaphylococcus lentus
Sillankorva, S., Neubauer, P. B., & Azeredo, J. (2010) · Biofouling · doi:10.1080/08927014.2010.494251 · Cited by 115
Co-evolution with lytic phage selects for the mucoid phenotype of Pseudomonas fluorescens SBW25
Scanlan, P. D., & Buckling, A. G. J. (2011) · The ISME Journal · doi:10.1038/ismej.2011.174 · Cited by 114
Effects of storage conditions on the stability of spray dried, inhalable bacteriophage powders
Leung, S. S. Y., Parumasivam, T., Gao, F. G., Carter, E. A., Carrigy, N. B., Vehring, R., Finlay, W. H., Morales, S., Britton, W. J., Kutter, E. M., et al. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.01.060 · Cited by 113
Molecular Basis for Lytic Bacteriophage Resistance in Enterococci
Duerkop, B. A., Huo, W., Bhardwaj, P., Palmer, K. L., & Hooper, L. V. (2016) · mBio · doi:10.1128/mbio.01304-16 · Cited by 112
The Lysis of Pathogenic Escherichia coli by Bacteriophages Releases Less Endotoxin Than by β-Lactams
Dufour, N., Delattre, R., Ricard, J.-D., & Debarbieux, L. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix184 · Cited by 112
German, G. J., & Misra, R. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4578 · Cited by 111
Constructing and Characterizing Bacteriophage Libraries for Phage Therapy of Human Infections
Gibson, S., Green, S. I., Liu, C. G., Salazar, K. C., Clark, J. R., Terwilliger, A. L., Kaplan, H. B., Maresso, A. W., Trautner, B. W., & Ramig, R. F. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02537 · Cited by 110
Majewska, J., Kaźmierczak, Z., Lahutta, K., Lecion, D., Szymczak, A., Miernikiewicz, P., Drapała, J., Harhala, M. A., Marek-Bukowiec, K., Jędruchniewicz, N., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02607 · Cited by 105
Steering Phages to Combat Bacterial Pathogens
Gurney, J., Brown, S. P., Kaltz, O., & Hochberg, M. (2019) · Trends in Microbiology · doi:10.1016/j.tim.2019.10.007 · Cited by 101
In Vitro Characteristics of Phages to Guide ‘Real Life’ Phage Therapy Suitability
Casey, E., van Sinderen, D., & Mahony, J. (2018) · Viruses · doi:10.3390/v10040163 · Cited by 100
Ferry, T., Boucher, F., Fèvre, C., Perpoint, T., Château, J., Petitjean, C., Josse, J., Chidiac, C., L’Hostis, G., Leboucher, G., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky263 · Cited by 100
The actvity of mouse Kupffer cells following intravenous injection of T4 bacteriophage.
Inchley, C. J. (1969) · PubMed Central · Cited by 98
Fish, R., Kutter, E. M., Wheat, G., Blasdel, B. G., Kutateladze, M., & Kuhl, S. J. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7395-8_14 · Cited by 91
Processing Phage Therapy Requests in a Brussels Military Hospital: Lessons Identified
Djebara, S., Maussen, C., Vos, D. D., Merabishvili, M., Damanet, B., Pang, K. W., Leenheer, P. D., Strachinaru, D. I. C., Soentjens, P. H. P., & Pirnay, J. (2019) · Viruses · doi:10.3390/v11030265 · Cited by 89
Gupta, R., & Prasad, Y. (2010) · Current Microbiology · doi:10.1007/s00284-010-9699-x · Cited by 88
Metagenomic Analysis of Therapeutic PYO Phage Cocktails from 1997 to 2014
Villarroel, J., Larsen, M., Kilstrup, M., & Nielsen, M. (2017) · Viruses · doi:10.3390/v9110328 · Cited by 86
Fate of Bacteriophage Particles Introduced into Mice by Various Routes.
Keller, R., & Engley, F. B. (1958) · Experimental Biology and Medicine · doi:10.3181/00379727-98-24112 · Cited by 85
Phage Genome Annotation Using the RAST Pipeline
McNair, K. A., Aziz, R. K., Pusch, G. D., Overbeek, R., Dutilh, B. E., & Edwards, R. A. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7343-9_17 · Cited by 85
Costa, P., Pereira, C., Gomes, A. T. P. C., & Almeida, A. (2019) · Microorganisms · doi:10.3390/microorganisms7040094 · Cited by 83
Dufour, N., Clermont, O., Combe, B. L., Messika, J., Dion, S., Khanna, V., Denamur, É., Ricard, J.-D., & Debarbieux, L. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw253 · Cited by 77
Belleghem, J. D. V., Merabishvili, M., Vergauwen, B., Lavigne, R., & Vaneechoutte, M. (2016) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2016.11.020 · Cited by 72
Chhibber, S., Kaur, S., & Bansal, S. (2015) · Microbiology · doi:10.1099/mic.0.000104 · Cited by 66
Host Exopolysaccharide Quantity and Composition Impact Erwinia amylovora Bacteriophage Pathogenesis
Roach, D. R., Sjaarda, D. R., Castle, A. J., & Svircev, A. M. (2013) · Applied and Environmental Microbiology · doi:10.1128/aem.00067-13 · Cited by 63
Self-citationMilho, C., Silva, M. D., Alves, D. F., Oliveira, H., Sousa, C. C. S., Pastrana, L. M., Azeredo, J., & Sillankorva, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-54847-y · Cited by 58
Ricci, V., & Piddock, L. J. V. (2010) · Applied and Environmental Microbiology · doi:10.1128/aem.02681-09 · Cited by 52
The multicomponent antirestriction system of phage P1 is linked to capsid morphogenesis
Piya, D., Vara, L., Russell, W. K., Young, R., & Gill, J. J. (2017) · Molecular Microbiology · doi:10.1111/mmi.13705 · Cited by 51
Rashid, S. J., Barylski, J., Hargreaves, K. R., Millard, A. D., Vinner, G. K., & Clokie, M. R. J. (2016) · Viruses · doi:10.3390/v8110310 · Cited by 35
Wei, Y., Ocampo, P., & Levin, B. R. (2010) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2010.0651 · Cited by 34
Shiley, J. R., Comfort, K. K., & Robinson, J. B. (2017) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-017-8504-1 · Cited by 30
Ultraviolet A and B wavelength-dependent inactivation of viruses and bacteria in the water
Mbonimpa, E. G., Blatchley, E. R., Applegate, B. M., & Harper, W. F. (2018) · Journal of Water and Health · doi:10.2166/wh.2018.071 · Cited by 29
Freyberger, H. R., He, Y., Roth, A. L., Nikolich, M. P., & Filippov, A. A. (2018) · Viruses · doi:10.3390/v10110617 · Cited by 28
Localization of cholera bacterio-phage after intravenous injection.
Mukerjee, S., & Ghosh, S. (1962) · PubMed · Cited by 12
Cited by
Phage Therapy for Antibiotic-Resistant Bacterial Infections
Hatfull, G. F., Dedrick, R. M., & Schooley, R. T. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-080219-122208 · Cited by 571
Considerations for the Use of Phage Therapy in Clinical Practice
Suh, G. A., Lodise, T. P., Tamma, P. D., Knisely, J. M., Alexander, J., Aslam, S., Barton, K. D., Bizzell, E., Totten, K. M. C., Campbell, J. L., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02071-21 · Cited by 378
An Overview of the Recent Advances in Antimicrobial Resistance
Oliveira, M., Antunes, W., Mota, S., Madureira-Carvalho, Á., Dinis-Oliveira, R. J., & Dias da Silva, D. (2024) · Microorganisms · doi:10.3390/microorganisms12091920 · Cited by 285
Salmonella Infection in Poultry: A Review on the Pathogen and Control Strategies
Shaji, S., Selvaraj, R. K., & Shanmugasundaram, R. (2023) · Microorganisms · doi:10.3390/microorganisms11112814 · Cited by 260
Menz, B. D., Charani, E., Gordon, D. L., Leather, A. J., Moonesinghe, S. R., & Phillips, C. J. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s319780 · Cited by 118
“are viruses with restricted bacterial activity often resulting in bacterial cell lysis.(163) To date, application and evidence of bacteriophage therapy is limited to small case studies and experimental trials.”
Background
Metadata
- Authors
- Luong, T., Salabarria, A.-C., & Roach, D. R.
- Venue
- Clinical Therapeutics
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 42
- Issue
- 9
- Pages
- 1659-1680
- ISSN
- 0149-2918 (ISSN-L)
- OpenAlex
- W3082973737
- Cited by
- 266
- References
- 142
- FWCI
- 14.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.